Credit: K KStock/Adobe stock

There has been a meteoric rise in popularity of the class of drugs commonly known as GLP-1s—including name brand drugs such as Ozempic and Wegovy. In addition, some plan sponsors have experienced a staggering increase in plan costs as a result of these drugs, which can run well over $1,000 per month. Initially approved to help diabetes patients control their blood sugar, drugs such as Ozempic have soared in popularity in recent years, in large part due to their popular side effect of rapid weight loss. Social media attention and popular culture references have fueled the rising awareness.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
C-Suite
Employee Participation
Employer-Paid